Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | GFER | P55789 | 2/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | BCL2 | P10415 | 1/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.40 |
| ▸ | FURIN | P09958 | 1/20 | 0.40 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14114075 | 1.00 | KDM4E (0.45) | KDM4EHPGDHTTGFERCASP3 | |
| SCHEMBL8449043 | 0.80 | PPARG (0.43) | HTTLMNARAB9ANPC1LOXL2 | |
| SCHEMBL7910552 | 0.80 | LPL (0.53) | — | |
| SCHEMBL16954571 | 0.79 | BCL2 (0.46) | BCL2SMYD3KAT6ACNR2LOXL2 | |
| SCHEMBL10178105 | 0.79 | CNR2 (0.42) | BCL2SMYD3KAT6ACNR2LOXL2 | |
| SCHEMBL21535793 | 0.79 | BCL2 (0.37) | KDM4EBCL2SMYD3FURINKAT6A | |
| SCHEMBL8469074 | 0.79 | PPARG (0.51) | HPGDHTTLMNACNR2RAB9A | |
| SCHEMBL27975833 | 0.78 | CYP4F2 (0.39) | BCL2SMYD3KAT6ACNR2LOXL2 | |
| SCHEMBL15896436 | 0.77 | PPARG (0.48) | — | |
| SCHEMBL1363307 | 0.76 | BCL2 (0.43) | BCL2SMYD3KAT6ACNR2LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076088-A1 | Thrombin Receptor Antagonists | SCHERING CORPORATION | 2009-03-19 | — | — | US | disclosed |
| US-20090069383-A1 | Thrombin Receptor Antagonists | SCHERING CORPORATION | 2009-03-12 | — | — | US | disclosed |
| US-7488742-B2 | Thrombin receptor antagonists | SCHERING CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-20040152736-A1 | Thrombin receptor antagonists | TOPROL ACQUISITION LLC | 2004-08-05 | — | — | US | disclosed |
| US-6172091-B1 | METABOLIC CALCIUM IMBALANCE AND OSTEOPOROSIS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2001-01-09 | — | — | US | disclosed |
| WO-2000021910-A2 | 1,2-DISUBSTITUTED CYCLOPROPANES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076088-A1 | Thrombin Receptor Antagonists | CNR1, CNR2, TBXA2R | KDM4E 4093/4885HPGD 969/4885HTT 3629/4885 |
| US-20040152736-A1 | Thrombin receptor antagonists | CNR1, TBXA2R, CNR2 | KDM4E 4442/4885HPGD 1055/4885HTT 3552/4885 |
| US-20090069383-A1 | Thrombin Receptor Antagonists | CNR1, CNR2, TBXA2R | KDM4E 4093/4885HPGD 969/4885HTT 3629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.